ImmunoGen, Inc.

IMGN
Real-time BATS EXCHANGE - 04/03 04:00:00 pm
3.41USD
-1.44%
Prev.3.4700
Open3.4000
High3.4850
Low3.2700
Volume1 571 733
Financials
Sales 2020 61,3 M
EBIT 2020 -105 M
Net income 2020 -106 M
Finance 2020 82,5 M
Yield 2020 -
P/E ratio 2020 -5,45x
P/E ratio 2021 -4,80x
EV / Sales2020 8,52x
EV / Sales2021 11,8x
Capitalization 605 M
Company
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2020-05-01 Earnings Release
Trading Rating :
Investor Rating :
Latest news
03/11IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
02/17IMMUNOGEN : Reports Recent Progress and 2019 Financial Results
AQ
02/14IMMUNOGEN : 4Q Earnings Snapshot
AQ
02/14IMMUNOGEN, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
02/14IMMUNOGEN : Reports Recent Progress and 2019 Financial Results
BU
02/06IMMUNOGEN : Announces Webcasts of Presentations at Upcoming Conferences
BU
02/04IMMUNOGEN : Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
02/03IMMUNOGEN : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishNeutral
Resistance3,893,896,80
Spread/Res.-12%-12%-50%
Spread/Supp.62%62%90%
Support2,122,121,80